Page last updated: 2024-08-17

tetrabenazine and Akinetic-Rigid Variant of Huntington Disease

tetrabenazine has been researched along with Akinetic-Rigid Variant of Huntington Disease in 122 studies

Research

Studies (122)

Timeframe	Studies, this research(%)	All Research%
pre-1990	36 (29.51)	18.7374
1990's	2 (1.64)	18.2507
2000's	16 (13.11)	29.6817
2010's	52 (42.62)	24.3611
2020's	16 (13.11)	2.80

Authors

Authors	Studies
Gros, Y; Schuldiner, S; Segal, T; Ugolev, Y; Yaffe, D	1
Leitinger, G; Maurer, C; Radulović, S; Sunkara, S	1
Bachoud-Levi, AC; Bentivoglio, AR; Burgunder, JM; Cardoso, F; Claassen, DO; Costa, J; Duarte, GS; Ferreira, JJ; Furr-Stimming, E; Kulisevsky, J; Landwehrmeyer, GB; Mestre, TA; Nirenberg, MJ; Rodrigues, FB; Rosser, A; Roth, J; Sampaio, C; Seppi, K; Slawek, J; Tabrizi, SJ; Vandenberghe, W; Walker, FO	1
Bharate, SS; Devadiga, SJ	1
Depoortere, R; Jastrzębska-Więsek, M; Kołaczkowski, M; Newman-Tancredi, A; Varney, MA; Wesołowska, A	1
Khan, MQ; Khan, ZQ; Masood, A; Mubeen, H; Nisa, AU; Wattoo, JI; Zafar, A	1
Belete, TM	1
Edmondson, MC; Frank, S; Goldstein, J; Gordon, MF; Gross, N; Kayson, E; Leavitt, BR; O'Neill, C; Oakes, D; Savola, JM; Testa, C; Vaughan, C; Whaley, J	1
Calopa, M; Ferré, A; Gamez, J; Huertas, O; Insa, R; Kulisevsky, J; McAllister, K; Muñoz, E; Reig, N; Scart-Grès, C	1
Heim, B; Seppi, K	1
Claassen, DO; Furr Stimming, E; Goldstein, J; Haubenberger, D; Kayson, E; Liang, GS; Mehanna, R; Zhang, H	1
Carroll, B; Claassen, DO; Philbin, M	1
Petersén, Å; Weydt, P	1
Baillie, TA; Bradbury, M; Cox, DS; Hellriegel, E; Loupe, PS; Rabinovich-Guilatt, L; Savola, JM; Schneider, F; Stamler, D	1
Rodrigues, FB; Wild, EJ	2
Ferreira, JJ; Leal Rato, M	1
McGarry, A	1
Dashtipour, K; Koch, J; Shi, WX	1
Claassen, DO; Gibson, JS	1
Paton, DM	1
Schmidt, C	1
Bozigian, H; Grigoriadis, DE; Loewen, G; O'Brien, CF; Skor, H; Smith, EB	1
Heo, YA; Scott, LJ	1
Abler, V; Claassen, DO; DiBonaventura, M; Gandhi, SK; Iyer, RG; Shah-Manek, B; Sung, VW	1
Jankovic, J; Niemann, N	1
Dean, M; Sung, VW	1
Ferreira, JJ; Rodrigues, FB; Wild, EJ	1
Chabal, CC; Kamholz, JA; Killoran, A; Moser, DJ; Nopoulos, PC; Schultz, JL	1
Bashir, H; Jankovic, J	1
Bednarczyk, EM; Russak, EM	1
Abler, V; Claassen, DO; DiBonaventura, M; Iyer, RG; Shah-Manek, B; Sung, VW	1
Frank, S; Richard, A	1
Aziz, NA	1
Schultz, JL	1
Macleod, M; Munafò, M; Sampaio, C; Wagenmakers, EJ; Ware, JJ	1
Kamholz, JA; Killoran, A; Moser, DJ; Nopoulos, PC; Schultz, JL	1
Cudkowicz, M; de Blieck, EA; Fung, WLA; Kieburtz, K; McCusker, E; McDermott, MP; McGarry, A; Peng, J	1
Shahani, L	1
Frank, S	2
Casaca-Carreira, J; Jahanshahi, A; Janssen, ML; Oosterloo, M; Santegoeds, RG; Temel, Y; Vlamings, R; Zeef, DH	1
Gupta, S; Sharma, B	1
Kawakami, D; Machida, K; Miki, M	1
Furukawa, Y; Ikeda, T; Ishida, C; Kato-Motozaki, Y; Komai, K; Nozaki, I; Tagami, A; Takahashi, K	1
Anderson, KE; Beck, CA; Biglan, KM; Brocht, AF; Darwin, KC; Dorsey, ER; Nichols, PE; Shoulson, I; Singh, S	1
Margolis, RL	1
Fiumedora, MM; Fritz, NE; Kegelmeyer, DA; Kloos, AD; Kostyk, SK; White, SE	1
Alusi, SH; Larner, AJ; Ziso, B	1
Geschwind, MD; Paras, N	1
Agarwal, P; Anderson, KE; Beck, C; Beland, M; Blindauer, KA; Boyd, JT; Brashers-Krug, T; Carlson, A; Chouinard, S; Christopher, E; Claassen, DO; Clouse, R; Colcher, A; Criswell, S; Davis, C; Dhall, R; Dubinsky, RM; Duker, A; Eberly, SW; Edicola, J; Edmondson, MC; Eglow, M; Esmail, S; Evans, S; Factor, SA; Fafard, L; Farbman, ES; Feigin, A; Frank, S; Fung, WL; Gibbons, C; Goldstein, J; Graffitti, L; Gray, C; Gudesblatt, M; Hackmyer, C; Heller, H; Herzog, M; Hickey, PT; Hohler, A; Houston, E; Hunter, C; James, RC; Janicki, S; Jankovic, J; Jimenez-Shahed, J; Kayson, E; Kerr, J; Kinel, S; Klos, K; Kumar, R; LaFaver, K; Leavitt, B; Margolis, RL; McGarry, A; Mendis, N; Mendis, T; Miller, A; Molho, E; Neefus, E; Nucifora, F; O'Neill, C; Oakes, D; Ong, M; Orme, C; Paulsen, JS; Qi, L; Quesada, M; Racette, BA; Reeves, C; Revilla, FJ; Rizer, K; Rodriguez, R; Roman, OC; Saint-Hilaire, M; Samii, A; Schneider, DP; Scott, BL; Shprecher, D; Singer, C; Smith, J; Snively, V; Sperin, E; Stamler, D; Sung, V; Suter, G; Tariot, PN; Testa, CM; Turpin, D; Vaughan, C; Wall, P; Watts, A; Whaley, J; Wheeler, L; Wilson-Perez, H; Wojcieszek, JM; Wong, C	1
Bonuccelli, U; Ceravolo, R; Mazzucchi, S; Palermo, G; Unti, E	1
Reilmann, R	1
Jankovic, J	2
Coppen, EM; Roos, RA	1
Morrow, T	1
Hayden, MR; Kirkpatrick, P; Leavitt, BR; Yasothan, U	1
Bernardi, G; Brusa, L; Iani, C; Mercuri, NB; Moschella, V; Orlacchio, A	1
Hussar, DA	1
Clark, J; Dobbins, EK; DuVall, CA; Neumiller, JJ; Santiago, A; Setter, SM; Wood, L	1
Chang, DJ; Jung, JK; Jung, JW; Kim, NJ; Moon, H; Paek, SM; Shin, D; Suh, YG	1
Frank, S; Jankovic, J	1
Kang, GA; Lee, AJ; Poon, LH	1
Guay, DR	1
Kazantsev, AG; Krobitsch, S	1
André, VM; Bardakjian, N; Cepeda, C; Fisher, YE; Huynh, M; Levine, MS; Singh, S; Yang, XW	1
Abdulrahman, GO	1
Scott, LJ	1
Cohen, HS; Davidson, A; Fekete, R; Ondo, WG	1
Pidgeon, C; Rickards, H	1
Chen, JJ; Dashtipour, K; Ondo, WG; Swope, DM	1
Davidson, A; Hunter, C; Jankovic, J; Jimenez-Shahed, J; Mehanna, R	1
Hersch, SM	1
MOLLER-CHRISTENSEN, B; VIDEBECH, T	1
Jankovic, J; Kenney, C	1
Davidson, A; Hunter, C; Jankovic, J; Kenney, C	1
Hunter, C; Jankovic, J; Kenney, C	1
Bonelli, RM; Hofmann, P	1
Login, IS; Savani, AA	1
Burke, RE; Fahn, S; Louis, K; Mayeux, R; Weinberg, H; Willner, JH	1
Mikkelsen, BO	1
Zaleska, B	1
Aminoff, MJ; Asher, SW	1
McLean, S; Millingen, KS; Roberts, MS; Watson, HM	1
Laterre, C; Ossemann, M; Sindic, CJ	1
Albin, RL; Bohnen, NI; Ficaro, E; Frey, KA; Kilbourn, MR; Koeppe, RA; Kuhl, DE; Meyer, P; Wernette, K	1
Albin, RL; Desmond, TJ; Frey, KA; Suzuki, M	1
Carolei, A; Del Castillo, G	1
Barbeau, A	1
Nyberg-Hansen, R	1
Buchan, AP; Couston, TA; Schneider, R	1
McArthur, AW; Pollock, M; Smidt, NA	1
Elliot, C; Holland, RT; Huang, CY; McLeod, JG	1
Kuran, W	1
McGlamery, M; Sambandham, RR; Toglia, JU	1
Chiu, E; Mann, J	1
Kingston, D	1
Chase, TN; Shoulson, I	1
Giménez-Roldán, S; Mateo, D; Muñoz-Blanco, JL	1
Giménez-Roldán, S; Mateo, D	1
Pearson, SJ; Reynolds, GP	1
Moss, JH; Stewart, DE	1
Jamali, F; Skelton, D; Watson, MW	1
Chalmers, RJ; Johnson, RH; McLellan, DL	1
Snaith, RP; Warren, HD	1
Astin, KJ; Gumpert, EW	1
Dalén, P	1
Pakkenberg, H	1
Dalby, MA	1
Fog, R; Pakkenberg, H	1
Soutar, CA	1
Heathfield, KW; Roberts, AH; Swash, M; Zakko, H	1
McLellan, DL	1
Gilligan, BS; Munro, OR; Veale, JL; Wodak, J	1
Chase, TN	1
Marsden, CD	1

Reviews

37 review(s) available for tetrabenazine and Akinetic-Rigid Variant of Huntington Disease

Article	Year
Digging Deeper: Advancements in Visualization of Inhibitory Synapses in Neurodegenerative Disorders. International journal of molecular sciences, 2021, Nov-18, Volume: 22, Issue:22 Topics: Alzheimer Disease; Amyotrophic Lateral Sclerosis; Animals; Brain; Humans; Huntington Disease; Levodopa; Memantine; Microscopy, Electron; Multiple Sclerosis; Neuronal Plasticity; Neurons; Neuroprotective Agents; Neurotransmitter Agents; Parkinson Disease; Synapses; Synaptic Transmission; Tetrabenazine	2021
An MDS Evidence-Based Review on Treatments for Huntington's Disease. Movement disorders : official journal of the Movement Disorder Society, 2022, Volume: 37, Issue:1 Topics: Apathy; Chorea; Humans; Huntington Disease; Movement Disorders; Tetrabenazine	2022
Recent developments in the management of Huntington's disease. Bioorganic chemistry, 2022, Volume: 120 Topics: Anxiety; Chorea; Humans; Huntington Disease; Tetrabenazine	2022
Recent Updates on the Development of Deuterium-Containing Drugs for the Treatment of Cancer. Drug design, development and therapy, 2022, Volume: 16 Topics: Carbon; Deuterium; Humans; Huntington Disease; Neoplasms; Tardive Dyskinesia; Tetrabenazine	2022
Deutetrabenazine for tardive dyskinesia and chorea associated with Huntington's disease: a review of clinical trial data. Expert opinion on pharmacotherapy, 2019, Volume: 20, Issue:18 Topics: Chorea; Dopamine Antagonists; Humans; Huntington Disease; Quality of Life; Tardive Dyskinesia; Tetrabenazine	2019
The psychopharmacology of Huntington disease. Handbook of clinical neurology, 2019, Volume: 165 Topics: Adrenergic Uptake Inhibitors; Humans; Huntington Disease; Psychopharmacology; Tetrabenazine; Vesicular Monoamine Transport Proteins	2019
VMAT2 inhibitors for the treatment of hyperkinetic movement disorders. Pharmacology & therapeutics, 2020, Volume: 212 Topics: Animals; Chorea; Clinical Trials as Topic; Dopamine; Humans; Huntington Disease; Hyperkinesis; Synaptic Transmission; Tardive Dyskinesia; Tetrabenazine; Vesicular Monoamine Transport Proteins	2020
Deutetrabenazine: Treatment of hyperkinetic aspects of Huntington's disease, tardive dyskinesia and Tourette syndrome. Drugs of today (Barcelona, Spain : 1998), 2017, Volume: 53, Issue:2 Topics: Adrenergic Uptake Inhibitors; Animals; Drug Approval; Heart Rate; Humans; Huntington Disease; Hyperkinesis; Molecular Structure; Motor Activity; Structure-Activity Relationship; Tardive Dyskinesia; Tetrabenazine; Tourette Syndrome; Treatment Outcome; United States; United States Food and Drug Administration	2017
Deutetrabenazine: A Review in Chorea Associated with Huntington's Disease. Drugs, 2017, Volume: 77, Issue:17 Topics: Administration, Oral; Chorea; Drug Interactions; Humans; Huntington Disease; Tetrabenazine; Vesicular Monoamine Transport Proteins	2017
Huntington’s Disease Clinical Trials Corner: February 2018 Journal of Huntington's disease, 2018, Volume: 7, Issue:1 Topics: Clinical Trials as Topic; Humans; Huntington Disease; Registries; Tetrabenazine; Treatment Outcome	2018
Treatment of Tardive Dyskinesia: A General Overview with Focus on the Vesicular Monoamine Transporter 2 Inhibitors. Drugs, 2018, Volume: 78, Issue:5 Topics: Antipsychotic Agents; Drug Approval; Humans; Huntington Disease; Tardive Dyskinesia; Tetrabenazine; Tourette Syndrome; United States; United States Food and Drug Administration; Valine; Vesicular Monoamine Transport Proteins	2018
Review of deutetrabenazine: a novel treatment for chorea associated with Huntington's disease. Drug design, development and therapy, 2018, Volume: 12 Topics: Adrenergic Uptake Inhibitors; Animals; Drug Administration Schedule; Drug Interactions; Humans; Huntington Disease; Tetrabenazine; Treatment Outcome; Vesicular Monoamine Transport Proteins	2018
Deutetrabenazine for the treatment of Huntington's chorea. Expert review of neurotherapeutics, 2018, Volume: 18, Issue:8 Topics: Adrenergic Uptake Inhibitors; Humans; Huntington Disease; Quality of Life; Tetrabenazine; Vesicular Monoamine Transport Proteins	2018
Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. The Annals of pharmacotherapy, 2019, Volume: 53, Issue:2 Topics: Chorea; Deuterium; Drug Approval; Humans; Huntington Disease; Legislation, Drug; Pharmaceutical Preparations; Pharmacokinetics; Tardive Dyskinesia; Tetrabenazine; Toxicity Tests; United States; United States Food and Drug Administration	2019
Deutetrabenazine in the treatment of Huntington's disease. Neurodegenerative disease management, 2019, Volume: 9, Issue:1 Topics: Adrenergic Uptake Inhibitors; Drug Interactions; Humans; Huntington Disease; Tetrabenazine; Treatment Outcome	2019
Treatment of Huntington's disease. Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics, 2014, Volume: 11, Issue:1 Topics: Adrenergic Uptake Inhibitors; Humans; Huntington Disease; Tetrabenazine	2014
[Pharmacological properties and clinical efficacy of tetrabenazine (Choreazine(®)Tablets 12.5 mg), a therapeutic agent for non-rhythmic involuntary movement]. Nihon yakurigaku zasshi. Folia pharmacologica Japonica, 2014, Volume: 143, Issue:3 Topics: Adrenergic Uptake Inhibitors; Animals; Biogenic Monoamines; Brain; Clinical Trials, Phase III as Topic; Disease Models, Animal; Humans; Huntington Disease; Male; Mice; Rats; Receptors, Dopamine D1; Tablets; Tetrabenazine; Time Factors; Vesicular Monoamine Transport Proteins	2014
[Tetrabenazine (tetrabenazine Orphan) orally]. Journal de pharmacie de Belgique, 2014, Issue:4 Topics: Administration, Oral; Adrenergic Uptake Inhibitors; Humans; Huntington Disease; Tetrabenazine	2014
Antipsychotic drugs in Huntington's disease. Expert review of neurotherapeutics, 2017, Volume: 17, Issue:3 Topics: Antipsychotic Agents; Humans; Huntington Disease; Piperidines; Tetrabenazine	2017
Dopamine depleters in the treatment of hyperkinetic movement disorders. Expert opinion on pharmacotherapy, 2016, Volume: 17, Issue:18 Topics: Animals; Antipsychotic Agents; Dopamine; Dopamine Antagonists; Humans; Huntington Disease; Hyperkinesis; Movement Disorders; Receptors, Dopamine; Tardive Dyskinesia; Tetrabenazine; Tics; Treatment Outcome	2016
Current Pharmacological Approaches to Reduce Chorea in Huntington's Disease. Drugs, 2017, Volume: 77, Issue:1 Topics: Antipsychotic Agents; Benzodiazepines; Humans; Huntington Disease; Olanzapine; Risperidone; Tetrabenazine; Tiapride Hydrochloride	2017
Tetrabenazine (Xenazine) for Huntington's chorea. The Medical letter on drugs and therapeutics, 2009, Jan-26, Volume: 51, Issue:1304 Topics: Animals; Controlled Clinical Trials as Topic; Depression; Humans; Huntington Disease; Tetrabenazine; Vesicular Monoamine Transport Proteins	2009
Treatment of chorea associated with Huntington's disease: focus on tetrabenazine. The Consultant pharmacist : the journal of the American Society of Consultant Pharmacists, 2009, Volume: 24, Issue:7 Topics: Adrenergic Uptake Inhibitors; Chorea; Clinical Trials as Topic; Drug Interactions; Humans; Huntington Disease; Patient Education as Topic; Tetrabenazine	2009
Advances in the pharmacological management of Huntington's disease. Drugs, 2010, Mar-26, Volume: 70, Issue:5 Topics: Animals; Antipsychotic Agents; Evidence-Based Medicine; Humans; Huntington Disease; Neuroprotective Agents; Tetrabenazine; Treatment Outcome	2010
Role of tetrabenazine for Huntington's disease-associated chorea. The Annals of pharmacotherapy, 2010, Volume: 44, Issue:6 Topics: Animals; Clinical Trials as Topic; Humans; Huntington Disease; Parkinsonian Disorders; Sleep Stages; Tetrabenazine	2010
Tetrabenazine, a monoamine-depleting drug used in the treatment of hyperkinetic movement disorders. The American journal of geriatric pharmacotherapy, 2010, Volume: 8, Issue:4 Topics: Adrenergic Uptake Inhibitors; Adult; Aged; Aged, 80 and over; Clinical Trials as Topic; Cytochrome P-450 CYP2D6; Depression; Dopamine; Drug Interactions; Genotype; Humans; Huntington Disease; Hyperkinesis; Middle Aged; Movement Disorders; Neuroleptic Malignant Syndrome; Parkinson Disease, Secondary; Quinolizines; Reserpine; Serotonin; Tetrabenazine; Vesicular Monoamine Transport Proteins; Young Adult	2010
Huntington's disease: From molecular basis to therapeutic advances. The international journal of biochemistry & cell biology, 2011, Volume: 43, Issue:1 Topics: Adrenergic Uptake Inhibitors; Animals; Cerebral Cortex; Disease Models, Animal; Humans; Huntingtin Protein; Huntington Disease; Mice; Mutation; Neostriatum; Nerve Tissue Proteins; Nuclear Proteins; Peptides; Protein Conformation; Tetrabenazine; Trinucleotide Repeats	2011
The pathophysiology and pharmacological treatment of Huntington disease. Behavioural neurology, 2013, Volume: 26, Issue:4 Topics: Antidepressive Agents; Antipsychotic Agents; Basal Ganglia; Cannabinoids; Cholinesterase Inhibitors; Excitatory Amino Acid Antagonists; GABA Agonists; Humans; Huntington Disease; Neuroprotective Agents; Tetrabenazine	2013
Tetrabenazine for the treatment of hyperkinetic movement disorders: a review of the literature. Clinical therapeutics, 2012, Volume: 34, Issue:7 Topics: Adrenergic Uptake Inhibitors; Animals; Chorea; Dystonia; Humans; Huntington Disease; Hyperkinesis; Movement Disorders; Rare Diseases; Tetrabenazine; Tic Disorders	2012
Huntington's disease: prospects for neuroprotective therapy 10 years after the discovery of the causative genetic mutation. Current opinion in neurology, 2003, Volume: 16, Issue:4 Topics: Amantadine; Anti-Dyskinesia Agents; Antiparkinson Agents; Eicosapentaenoic Acid; Fatty Acids, Unsaturated; Humans; Huntingtin Protein; Huntington Disease; Nerve Degeneration; Nerve Tissue Proteins; Neuroprotective Agents; Nuclear Proteins; Point Mutation; Riluzole; Tetrabenazine; Time Factors	2003
Tetrabenazine in the treatment of hyperkinetic movement disorders. Expert review of neurotherapeutics, 2006, Volume: 6, Issue:1 Topics: Adrenergic Uptake Inhibitors; Clinical Trials as Topic; Drug Tolerance; Expert Testimony; Humans; Huntington Disease; Hyperkinesis; Movement Disorders; Tetrabenazine	2006
A systematic review of the treatment studies in Huntington's disease since 1990. Expert opinion on pharmacotherapy, 2007, Volume: 8, Issue:2 Topics: Amantadine; Antipsychotic Agents; Chorea; Depression; Humans; Huntington Disease; Neuroprotective Agents; Riluzole; Sexual Dysfunctions, Psychological; Tetrabenazine	2007
[Progress in the treatment of degenerative diseases of the nervous system. Selected problems]. Neurologia i neurochirurgia polska, 1980, Volume: 14, Issue:2 Topics: Amyotrophic Lateral Sclerosis; Antiparkinson Agents; Humans; Huntington Disease; Lithium; Neostigmine; Parkinson Disease; Penicillamine; Phthalazines; Selegiline; Tetrabenazine; Tiapamil Hydrochloride	1980
[Recent neurobiological and related pharmaco-therapeutic acquisitions in Huntington's chorea]. La Clinica terapeutica, 1979, Sep-30, Volume: 90, Issue:6 Topics: Amphetamine; Antipsychotic Agents; Brain; Butyrophenones; gamma-Aminobutyric Acid; Humans; Huntington Disease; Kainic Acid; Levodopa; Lithium; Neurotransmitter Agents; Phenothiazines; Sympatholytics; Tetrabenazine	1979
Progress in understanding Huntington's chorea. The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques, 1975, Volume: 2, Issue:2 Topics: Acetylcholine; Acetylcholinesterase; Basal Ganglia; Blood-Brain Barrier; Brain; Catecholamines; Caudate Nucleus; Dopamine; gamma-Aminobutyric Acid; Glutamate Decarboxylase; Homovanillic Acid; Humans; Huntington Disease; Hypothalamus; Parasympatholytics; Physostigmine; Receptors, Adrenergic; Receptors, Cholinergic; Tetrabenazine	1975
Huntington's disease. Annual review of medicine, 1975, Volume: 26 Topics: Adult; Child; Chlordiazepoxide; Diazepam; Dopamine; Female; Genetic Counseling; Haloperidol; Humans; Huntington Disease; Male; Perphenazine; Psychotherapy; Secologanin Tryptamine Alkaloids; Synaptic Transmission; Tetrabenazine	1975
Serotonergic mechanisms and extrapyramidal function in man. Advances in neurology, 1974, Volume: 5 Topics: 5-Hydroxytryptophan; Carbidopa; Cerebellar Diseases; Creutzfeldt-Jakob Syndrome; Down Syndrome; Extrapyramidal Tracts; Fenclonine; Homovanillic Acid; Humans; Huntington Disease; Hydroxyindoleacetic Acid; Imipramine; Levodopa; Muscular Diseases; Paralysis; Parkinson Disease; Parkinson Disease, Secondary; Probenecid; Reserpine; Serotonin; Spinal Cord Diseases; Tetrabenazine; Time Factors	1974

Trials

15 trial(s) available for tetrabenazine and Akinetic-Rigid Variant of Huntington Disease

Article	Year
The Safety of Deutetrabenazine for Chorea in Huntington Disease: An Open-Label Extension Study. CNS drugs, 2022, Volume: 36, Issue:11 Topics: Chorea; Double-Blind Method; Humans; Huntington Disease; Tetrabenazine; Treatment Outcome	2022
A proof-of-concept study with SOM3355 (bevantolol hydrochloride) for reducing chorea in Huntington's disease. British journal of clinical pharmacology, 2023, Volume: 89, Issue:5 Topics: Chorea; Double-Blind Method; Humans; Huntington Disease; Tetrabenazine; Treatment Outcome; Vesicular Monoamine Transport Proteins	2023
Safety and efficacy of valbenazine for the treatment of chorea associated with Huntington's disease (KINECT-HD): a phase 3, randomised, double-blind, placebo-controlled trial. The Lancet. Neurology, 2023, Volume: 22, Issue:6 Topics: Adult; Antipsychotic Agents; Chorea; Double-Blind Method; Female; Humans; Huntington Disease; Male; Tetrabenazine; Treatment Outcome	2023
Pharmacokinetic and Metabolic Profile of Deutetrabenazine (TEV-50717) Compared With Tetrabenazine in Healthy Volunteers. Clinical and translational science, 2020, Volume: 13, Issue:4 Topics: Administration, Oral; Adolescent; Adrenergic Uptake Inhibitors; Adult; Area Under Curve; Cross-Over Studies; Female; Healthy Volunteers; Humans; Huntington Disease; Male; Tardive Dyskinesia; Tetrabenazine; Young Adult	2020
Effect of Deutetrabenazine on Chorea Among Patients With Huntington Disease: A Randomized Clinical Trial. JAMA, 2016, Jul-05, Volume: 316, Issue:1 Topics: Adrenergic Uptake Inhibitors; Chorea; Cytochrome P-450 CYP2D6; Double-Blind Method; Drug Administration Schedule; Female; Humans; Huntington Disease; Maintenance Chemotherapy; Male; Middle Aged; Tetrabenazine; Treatment Outcome	2016
Treatment of the symptoms of Huntington's disease: preliminary results comparing aripiprazole and tetrabenazine. Movement disorders : official journal of the Movement Disorder Society, 2009, Jan-15, Volume: 24, Issue:1 Topics: Adult; Aged; Aripiprazole; Cross-Over Studies; Dopamine Agents; Dyskinesia, Drug-Induced; Female; Humans; Huntingtin Protein; Huntington Disease; Hyperkinesis; Male; Middle Aged; Nerve Tissue Proteins; Nuclear Proteins; Piperazines; Quinolones; Receptors, Dopamine D2; Tetrabenazine; Trinucleotide Repeats	2009
Tetrabenazine as anti-chorea therapy in Huntington disease: an open-label continuation study. Huntington Study Group/TETRA-HD Investigators. BMC neurology, 2009, Dec-18, Volume: 9 Topics: Adrenergic Uptake Inhibitors; Adult; Aged; Disability Evaluation; Double-Blind Method; Drug Evaluation; Follow-Up Studies; Humans; Huntington Disease; Middle Aged; Severity of Illness Index; Tetrabenazine; Time Factors; Treatment Outcome	2009
Tetrabenazine as antichorea therapy in Huntington disease: a randomized controlled trial. Neurology, 2006, Feb-14, Volume: 66, Issue:3 Topics: Accidental Falls; Anti-Dyskinesia Agents; Breast Neoplasms; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Huntington Disease; Psychomotor Agitation; Suicide; Tetrabenazine; Treatment Outcome	2006
Short-term effects of tetrabenazine on chorea associated with Huntington's disease. Movement disorders : official journal of the Movement Disorder Society, 2007, Volume: 22, Issue:1 Topics: Adult; Aged; Anti-Dyskinesia Agents; Chorea; Female; Humans; Huntington Disease; Male; Middle Aged; Severity of Illness Index; Tetrabenazine; Time Factors	2007
Tetrabenazine and movement disorders. Neurology, 1981, Volume: 31, Issue:8 Topics: Adult; Aged; Clinical Trials as Topic; Double-Blind Method; Dyskinesia, Drug-Induced; Dystonia; Female; Humans; Huntington Disease; Male; Middle Aged; Movement Disorders; Tetrabenazine	1981
Treatment of hyperkinetic movement disorders with tetrabenazine: a double-blind crossover study. Annals of neurology, 1982, Volume: 11, Issue:1 Topics: Adolescent; Adult; Aged; Athetosis; Blepharospasm; Child; Chorea; Clinical Trials as Topic; Double-Blind Method; Dyskinesia, Drug-Induced; Dystonia; Dystonia Musculorum Deformans; Female; Humans; Huntington Disease; Male; Middle Aged; Neuromuscular Diseases; Tetrabenazine	1982
[Huntington disease: tetrabenazine compared to haloperidol in the reduction of involuntary movements]. Neurologia (Barcelona, Spain), 1989, Volume: 4, Issue:8 Topics: Adult; Drug Evaluation; Female; Haloperidol; Humans; Huntington Disease; Male; Middle Aged; Random Allocation; Tetrabenazine	1989
A double-blind trial of tetrabenazine, thiopropazate, and placebo in patients with chorea. Lancet (London, England), 1974, Jan-26, Volume: 1, Issue:7848 Topics: Adult; Clinical Trials as Topic; Diseases in Twins; Dopamine; Drug Evaluation; Female; Homovanillic Acid; Humans; Huntington Disease; Male; Middle Aged; Neurologic Manifestations; Neurotic Disorders; Parkinson Disease, Secondary; Phenothiazines; Placebos; Serotonin; Tetrabenazine	1974
Letter: Lithium and Huntington's chorea. Lancet (London, England), 1974, Mar-30, Volume: 1, Issue:7857 Topics: Clinical Trials as Topic; Drug Antagonism; Drug Therapy, Combination; Humans; Huntington Disease; Lithium; Phenothiazines; Tetrabenazine	1974
Tetrabenazine in the treatment of extrapyramidal dyskinesias. The Medical journal of Australia, 1972, Nov-04, Volume: 2, Issue:19 Topics: Adolescent; Adult; Athetosis; Basal Ganglia Diseases; Chorea; Clinical Trials as Topic; Female; Humans; Huntington Disease; Male; Middle Aged; Movement Disorders; Placebos; Spasm; Tetrabenazine	1972

Other Studies

70 other study(ies) available for tetrabenazine and Akinetic-Rigid Variant of Huntington Disease

Article	Year
Identification of conformationally sensitive residues essential for inhibition of vesicular monoamine transport by the noncompetitive inhibitor tetrabenazine. The Journal of biological chemistry, 2013, Nov-08, Volume: 288, Issue:45 Topics: Adrenergic Uptake Inhibitors; Animals; Binding Sites; Biological Transport, Active; HEK293 Cells; Humans; Huntington Disease; Mutagenesis, Site-Directed; Protein Structure, Secondary; Rats; Saccharomyces cerevisiae; Tetrabenazine; Tourette Syndrome; Vesicular Monoamine Transport Proteins	2013
The selective 5-HT 1A receptor agonist, NLX-112, overcomes tetrabenazine-induced catalepsy and depression-like behavior in the rat. Behavioural pharmacology, 2022, 08-01, Volume: 33, Issue:5 Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Animals; Antidepressive Agents; Buspirone; Catalepsy; Depression; Huntington Disease; Parkinsonian Disorders; Piperidines; Pyridines; Rats; Receptor, Serotonin, 5-HT1A; Serotonin; Serotonin 5-HT1 Receptor Agonists; Serotonin Receptor Agonists; Tetrabenazine	2022
Computational insights into missense mutations in HTT gene causing Huntington's disease and its interactome networks. Irish journal of medical science, 2023, Volume: 192, Issue:3 Topics: Amino Acids; Brain-Derived Neurotrophic Factor; Humans; Huntingtin Protein; Huntington Disease; Ligands; Molecular Docking Simulation; Mutation, Missense; Tetrabenazine	2023
Valbenazine as treatment for Huntington's disease chorea. The Lancet. Neurology, 2023, Volume: 22, Issue:6 Topics: Chorea; Humans; Huntington Disease; Tetrabenazine; Valine	2023
Huntington's Disease Clinical Trials Corner: April 2020. Journal of Huntington's disease, 2020, Volume: 9, Issue:2 Topics: Clinical Trials as Topic; Genetic Therapy; Humans; Huntington Disease; Randomized Controlled Trials as Topic; Tetrabenazine; Valine; Vesicular Monoamine Transport Proteins	2020
Reader response: Risk factors for suicidality in Huntington disease: An analysis of the 2CARE clinical trial. Neurology, 2020, 04-07, Volume: 94, Issue:14 Topics: Humans; Huntington Disease; Risk Factors; Suicidal Ideation; Suicide; Tetrabenazine	2020
Author response: Risk factors for suicidality in Huntington disease: An analysis of the 2CARE clinical trial. Neurology, 2020, 04-07, Volume: 94, Issue:14 Topics: Humans; Huntington Disease; Risk Factors; Suicidal Ideation; Suicide; Tetrabenazine	2020
State-of-the-art pharmacological approaches to reduce chorea in Huntington's disease. Expert opinion on pharmacotherapy, 2021, Volume: 22, Issue:8 Topics: Antipsychotic Agents; Chorea; Humans; Huntington Disease; Prospective Studies; Tetrabenazine	2021
First deuterated drug approved. Nature biotechnology, 2017, 06-07, Volume: 35, Issue:6 Topics: Deuterium; Drug Approval; Drug Industry; Humans; Huntington Disease; Tetrabenazine; United States; United States Food and Drug Administration	2017
Differences in Dihydrotetrabenazine Isomer Concentrations Following Administration of Tetrabenazine and Valbenazine. Drugs in R&D, 2017, Volume: 17, Issue:3 Topics: Adrenergic Uptake Inhibitors; Adult; Chromatography, Liquid; Female; Humans; Huntington Disease; Isomerism; Male; Middle Aged; Tandem Mass Spectrometry; Tardive Dyskinesia; Tetrabenazine; Valine	2017
Physician perceptions of pharmacologic treatment options for chorea associated with Huntington disease in the United States. Current medical research and opinion, 2018, Volume: 34, Issue:4 Topics: Activities of Daily Living; Adult; Aged; Chorea; Cross-Sectional Studies; Depression; Female; Humans; Huntington Disease; Male; Middle Aged; Perception; Physicians; Quality of Life; Surveys and Questionnaires; Tetrabenazine; United States	2018
Deutetrabenazine (Austedo) for Huntington's chorea and tardive dyskinesia. The Medical letter on drugs and therapeutics, 2018, 04-23, Volume: 60, Issue:1545 Topics: Adrenergic Uptake Inhibitors; Drug Costs; Drug Interactions; Humans; Huntington Disease; Tardive Dyskinesia; Tetrabenazine; Treatment Outcome; Vesicular Monoamine Transport Proteins	2018
Physician perception versus true efficacy of tetrabenazine for Huntington's disease. Current medical research and opinion, 2018, Volume: 34, Issue:9 Topics: Chorea; Humans; Huntington Disease; Physicians; Tetrabenazine; United States	2018
Evaluating depression and suicidality in tetrabenazine users with Huntington disease. Neurology, 2018, 07-17, Volume: 91, Issue:3 Topics: Adrenergic Uptake Inhibitors; Adult; Aged; Depression; Female; Humans; Huntington Disease; Longitudinal Studies; Male; Middle Aged; Suicidal Ideation; Tetrabenazine; Vesicular Monoamine Transport Proteins	2018
Tetrabenazine Treatment Patterns and Outcomes for Chorea Associated with Huntington Disease: A Retrospective Chart Review. Journal of Huntington's disease, 2018, Volume: 7, Issue:4 Topics: Adrenergic Uptake Inhibitors; Adult; Aged; Emergency Service, Hospital; Female; Hospitalization; Humans; Huntington Disease; Length of Stay; Male; Medication Adherence; Middle Aged; Neurologists; Practice Patterns, Physicians'; Retrospective Studies; Severity of Illness Index; Tetrabenazine	2018
Reader response: Evaluating depression and suicidality in tetrabenazine users with Huntington disease. Neurology, 2019, 02-26, Volume: 92, Issue:9 Topics: Depression; Depressive Disorder; Humans; Huntington Disease; Suicide; Tetrabenazine	2019
Author response: Evaluating depression and suicidality in tetrabenazine users with Huntington disease. Neurology, 2019, 02-26, Volume: 92, Issue:9 Topics: Depression; Depressive Disorder; Humans; Huntington Disease; Suicide; Tetrabenazine	2019
Reader response: Evaluating depression and suicidality in tetrabenazine users with Huntington disease. Neurology, 2019, 02-26, Volume: 92, Issue:9 Topics: Depression; Depressive Disorder; Humans; Huntington Disease; Suicide; Tetrabenazine	2019
Author response: Evaluating depression and suicidality in tetrabenazine users with Huntington disease. Neurology, 2019, 02-26, Volume: 92, Issue:9 Topics: Depression; Depressive Disorder; Humans; Huntington Disease; Suicide; Tetrabenazine	2019
Risk factors for suicidality in Huntington disease: An analysis of the 2CARE clinical trial. Neurology, 2019, 04-02, Volume: 92, Issue:14 Topics: Adrenergic Uptake Inhibitors; Adult; Anti-Anxiety Agents; Antidepressive Agents; Anxiety Disorders; Bipolar Disorder; Depressive Disorder; Employment; Female; Humans; Huntingtin Protein; Huntington Disease; Male; Marital Status; Middle Aged; Randomized Controlled Trials as Topic; Risk Factors; Suicidal Ideation; Suicide, Attempted; Tetrabenazine; Trinucleotide Repeat Expansion; Ubiquinone; Vitamins	2019
Tetrabenazine and suicidal ideation. The Journal of neuropsychiatry and clinical neurosciences, 2013,Winter, Volume: 25, Issue:1 Topics: Adrenergic Uptake Inhibitors; Depression; Female; Humans; Huntington Disease; Middle Aged; Suicidal Ideation; Tetrabenazine	2013
An experimental model for Huntington's chorea? Behavioural brain research, 2014, Apr-01, Volume: 262 Topics: Adrenergic Uptake Inhibitors; Animals; Disease Models, Animal; Huntington Disease; Hyperkinesis; Male; Rats; Rats, Transgenic; Tetrabenazine	2014
Pharmacological benefit of I(1)-imidazoline receptors activation and nuclear factor kappa-B (NF-κB) modulation in experimental Huntington's disease. Brain research bulletin, 2014, Volume: 102 Topics: Adrenergic Uptake Inhibitors; Animals; Anxiety; Brain; Disease Models, Animal; Ditiocarb; Huntington Disease; Imidazoles; Imidazoline Receptors; Learning Disabilities; Memory Disorders; Motor Activity; NF-kappa B; Nitro Compounds; Nootropic Agents; Oxidative Stress; Propionates; Rats; Rats, Wistar; Tetrabenazine	2014
Neuroleptic malignant syndrome induced by combination therapy with tetrabenazine and tiapride in a Japanese patient with Huntington's disease at the terminal stage of recurrent breast cancer. Internal medicine (Tokyo, Japan), 2014, Volume: 53, Issue:11 Topics: Adrenergic Uptake Inhibitors; Adult; Aged, 80 and over; Antipsychotic Agents; Breast Neoplasms; Dopamine Antagonists; Drug Therapy, Combination; Female; Humans; Huntington Disease; Middle Aged; Neoplasm Recurrence, Local; Neuroleptic Malignant Syndrome; Tetrabenazine; Tiapride Hydrochloride	2014
Depressed mood and suicidality in individuals exposed to tetrabenazine in a large Huntington disease observational study. Journal of Huntington's disease, 2013, Volume: 2, Issue:4 Topics: Adrenergic Uptake Inhibitors; Adult; Depression; Female; Humans; Huntington Disease; Male; Middle Aged; Suicidal Ideation; Tetrabenazine	2013
Tetrabenazine, depression and suicide: good news. Journal of Huntington's disease, 2014, Volume: 3, Issue:2 Topics: Adrenergic Uptake Inhibitors; Depression; Humans; Huntington Disease; Suicide; Tetrabenazine	2014
Impact of tetrabenazine on gait and functional mobility in individuals with Huntington's disease. Journal of the neurological sciences, 2014, Dec-15, Volume: 347, Issue:1-2 Topics: Adrenergic Uptake Inhibitors; Adult; Aged; Female; Gait; Humans; Huntington Disease; Male; Middle Aged; Motor Activity; Tetrabenazine; Treatment Outcome	2014
Stuck in the middle: Huntington's disease or not Huntington's disease? The Journal of neuropsychiatry and clinical neurosciences, 2015,Winter, Volume: 27, Issue:1 Topics: Adrenergic Uptake Inhibitors; Aged; Female; Humans; Huntingtin Protein; Huntington Disease; Nerve Tissue Proteins; Tetrabenazine; Trinucleotide Repeats	2015
Deutetrabenazine for Treatment of Chorea in Huntington Disease. JAMA, 2016, Jul-05, Volume: 316, Issue:1 Topics: Adrenergic Uptake Inhibitors; Chorea; Female; Humans; Huntington Disease; Male; Tetrabenazine	2016
Deutetrabenazine-Not a Revolution but Welcome Evolution for Treating Chorea in Huntington Disease. JAMA neurology, 2016, 12-01, Volume: 73, Issue:12 Topics: Humans; Huntington Disease; Neurotransmitter Uptake Inhibitors; Tetrabenazine	2016
Gene therapy offers HD patients relief from some symptoms. Tetrabenazine inhibits the transport of a molecule called vesicular monoamine transporter type 2 or VMAT2. Managed care (Langhorne, Pa.), 2008, Volume: 17, Issue:11 Topics: Adrenergic Uptake Inhibitors; Genetic Therapy; Humans; Huntington Disease; Tetrabenazine; Vesicular Monoamine Transport Proteins	2008
Tetrabenazine. Nature reviews. Drug discovery, 2009, Volume: 8, Issue:1 Topics: Adrenergic Uptake Inhibitors; Chorea; Clinical Trials as Topic; Drug Approval; Humans; Huntington Disease; Tetrabenazine; United States; United States Food and Drug Administration	2009
New drugs 09, part 2. Nursing, 2009, Volume: 39, Issue:6 Topics: Adrenergic Uptake Inhibitors; Angioedemas, Hereditary; Benzoates; Carrier Proteins; Complement C1 Inactivator Proteins; Complement C1 Inhibitor Protein; Drug Approval; Drug Therapy; Drug-Related Side Effects and Adverse Reactions; Fluprednisolone; Humans; Huntington Disease; Hydrazines; Keratitis; Nurse's Role; Ophthalmologic Surgical Procedures; Pain, Postoperative; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Pyridines; Receptors, Fc; Recombinant Fusion Proteins; Tetrabenazine; Thrombopoietin; Uveitis	2009
A concise total synthesis of (+)-tetrabenazine and (+)-α-dihydrotetrabenazine. Chemistry (Weinheim an der Bergstrasse, Germany), 2010, Apr-19, Volume: 16, Issue:15 Topics: Cholera; Huntington Disease; Molecular Structure; Stereoisomerism; Tetrabenazine	2010
Differential electrophysiological changes in striatal output neurons in Huntington's disease. The Journal of neuroscience : the official journal of the Society for Neuroscience, 2011, Jan-26, Volume: 31, Issue:4 Topics: Action Potentials; Age Factors; Animals; Corpus Striatum; Dendritic Spines; Dopamine; Excitatory Postsynaptic Potentials; Glutamic Acid; Green Fluorescent Proteins; Huntington Disease; In Vitro Techniques; Mice; Mice, Mutant Strains; Motor Activity; Neurons; Promoter Regions, Genetic; Receptors, Dopamine D1; Receptors, Dopamine D2; Stereotyped Behavior; Synaptic Transmission; Tetrabenazine	2011
Therapeutic advances in the management of Huntington's disease. The Yale journal of biology and medicine, 2011, Volume: 84, Issue:3 Topics: Cystamine; Humans; Huntington Disease; Peptides; Recombinant Fusion Proteins; RNA Interference; Single-Chain Antibodies; Tetrabenazine; Transglutaminases; Trinucleotide Repeat Expansion	2011
Tetrabenazine: for chorea associated with Huntington's disease. CNS drugs, 2011, Dec-01, Volume: 25, Issue:12 Topics: Animals; Chorea; Clinical Trials as Topic; Dopamine; Double-Blind Method; Drug Evaluation, Preclinical; Humans; Huntington Disease; Multicenter Studies as Topic; Randomized Controlled Trials as Topic; Tetrabenazine; Vesicular Monoamine Transport Proteins	2011
Effect of tetrabenazine on computerized dynamic posturography in Huntington disease patients. Parkinsonism & related disorders, 2012, Volume: 18, Issue:7 Topics: Adult; Aged; Cues; Female; Humans; Huntington Disease; Male; Middle Aged; Postural Balance; Tetrabenazine; Vision, Ocular	2012
Analysis of CYP2D6 genotype and response to tetrabenazine. Movement disorders : official journal of the Movement Disorder Society, 2013, Volume: 28, Issue:2 Topics: Adult; Anti-Dyskinesia Agents; Cytochrome P-450 CYP2D6; Female; Genotype; Humans; Huntington Disease; Hyperkinesis; Male; Middle Aged; Movement Disorders; Myoclonus; Pharmacogenetics; Phenotype; Psychomotor Agitation; Tetrabenazine; Tourette Syndrome; Treatment Outcome	2013
[Treatment of Huntington's chorea with tetrabenazine (Nitoman)]. Ugeskrift for laeger, 1963, Feb-08, Volume: 125 Topics: Chorea; Humans; Huntington Disease; Tetrabenazine	1963
Long-term tolerability of tetrabenazine in the treatment of hyperkinetic movement disorders. Movement disorders : official journal of the Movement Disorder Society, 2007, Jan-15, Volume: 22, Issue:2 Topics: Adult; Age of Onset; Anti-Dyskinesia Agents; Drug Administration Schedule; Drug Tolerance; Dyskinesia, Drug-Induced; Female; Humans; Huntington Disease; Hyperkinesis; Male; Middle Aged; Myoclonus; Parkinsonian Disorders; Prevalence; Retrospective Studies; Severity of Illness Index; Tetrabenazine; Tics; Time	2007
Tetrabenazine as antichorea therapy in Huntington disease: a randomized controlled trial. Neurology, 2007, Mar-06, Volume: 68, Issue:10 Topics: Anti-Dyskinesia Agents; Chorea; Humans; Huntington Disease; Randomized Controlled Trials as Topic; Tetrabenazine	2007
Neuroleptic malignant syndrome caused by dopamine-depleting drugs in a patient with Huntington disease. Neurology, 1981, Volume: 31, Issue:8 Topics: Adolescent; Adult; alpha-Methyltyrosine; Antipsychotic Agents; Child; Dopamine; Dystonia; Female; Fever; Humans; Huntington Disease; Male; Malignant Hyperthermia; Methyltyrosines; Syndrome; Tetrabenazine	1981
Tolerance of tetrabenazine during long-term treatment. Acta neurologica Scandinavica, 1983, Volume: 68, Issue:1 Topics: Aged; Drug Tolerance; Dyskinesia, Drug-Induced; Female; Humans; Huntington Disease; Long-Term Care; Male; Middle Aged; Tetrabenazine	1983
Determination of therapeutic plasma concentrations of tetrabenazine and an active metabolite by high-performance liquid chromatography. Journal of chromatography, 1981, Nov-13, Volume: 226, Issue:1 Topics: Chromatography, High Pressure Liquid; Humans; Huntington Disease; Tetrabenazine; Time Factors	1981
Tetrabenazine as a cause of neuroleptic malignant syndrome. Movement disorders : official journal of the Movement Disorder Society, 1996, Volume: 11, Issue:1 Topics: Anti-Dyskinesia Agents; Dose-Response Relationship, Drug; Humans; Huntington Disease; Long-Term Care; Male; Middle Aged; Neuroleptic Malignant Syndrome; Tetrabenazine	1996
Decreased striatal monoaminergic terminals in Huntington disease. Neurology, 2000, May-09, Volume: 54, Issue:9 Topics: Adult; Aged; Brain Mapping; Corpus Striatum; Female; Humans; Huntington Disease; Male; Membrane Glycoproteins; Membrane Transport Proteins; Middle Aged; Neuropeptides; Neurotransmitter Agents; Predictive Value of Tests; Substantia Nigra; Tetrabenazine; Tomography, Emission-Computed; Vesicular Biogenic Amine Transport Proteins; Vesicular Monoamine Transport Proteins	2000
Vesicular neurotransmitter transporters in Huntington's disease: initial observations and comparison with traditional synaptic markers. Synapse (New York, N.Y.), 2001, Sep-15, Volume: 41, Issue:4 Topics: Adult; Aged; Aged, 80 and over; Animals; Autoradiography; Carrier Proteins; Choline O-Acetyltransferase; Cholinergic Fibers; Corpus Striatum; Dopamine Plasma Membrane Transport Proteins; Female; Flumazenil; GABA Modulators; Humans; Huntington Disease; Male; Membrane Glycoproteins; Membrane Transport Proteins; Middle Aged; Nerve Tissue Proteins; Neuropeptides; Postmortem Changes; Rats; Rats, Sprague-Dawley; Receptors, Dopamine D2; Receptors, GABA-A; Substantia Nigra; Synapses; Tetrabenazine; Tritium; Vesicular Acetylcholine Transport Proteins; Vesicular Biogenic Amine Transport Proteins; Vesicular Monoamine Transport Proteins; Vesicular Transport Proteins	2001
[Editorial: Treatment of choriatic movements]. Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke, 1975, Nov-30, Volume: 95, Issue:33 Topics: Chorea; Humans; Huntington Disease; Lithium; Tetrabenazine; Tranquilizing Agents	1975
Letter: Low-dosage treatment with tetrabenazine. British medical journal, 1976, May-15, Volume: 1, Issue:6019 Topics: Female; Humans; Huntington Disease; Middle Aged; Tetrabenazine	1976
Combined therapy with tetrabenazine and pimozide in Huntington's chorea: pilot study. The New Zealand medical journal, 1976, Feb-25, Volume: 83, Issue:558 Topics: Adult; Drug Therapy, Combination; Female; Humans; Huntington Disease; Male; Pilot Projects; Pimozide; Placebos; Tetrabenazine	1976
Tetrabenazine in the treatment of Huntington's chorea. The Medical journal of Australia, 1976, Apr-17, Volume: 1, Issue:16 Topics: Adult; Bronchopneumonia; Deglutition Disorders; Female; Humans; Huntington Disease; Hypotension, Orthostatic; Male; Middle Aged; Tetrabenazine	1976
[Modern methods of treating Huntington's chorea]. Polski tygodnik lekarski (Warsaw, Poland : 1960), 1976, Aug-09, Volume: 31, Issue:32 Topics: gamma-Aminobutyric Acid; Haloperidol; Humans; Huntington Disease; Lithium; Methysergide; Physostigmine; Tetrabenazine	1976
Tetrabenazine in the treatment of Huntington's chorea and other hyperkinetic movement disorders. The Journal of clinical psychiatry, 1978, Volume: 39, Issue:1 Topics: Adult; Aged; Dose-Response Relationship, Drug; Female; Humans; Huntington Disease; Male; Middle Aged; Motor Skills; Psychomotor Disorders; Tetrabenazine	1978
Platelet monoamine oxidase activity in Huntington's chorea. Journal of neurology, neurosurgery, and psychiatry, 1978, Volume: 41, Issue:9 Topics: Adult; Aged; Blood Platelets; Female; Haloperidol; Humans; Huntington Disease; Lithium; Male; Middle Aged; Monoamine Oxidase; Pimozide; Sex Factors; Tetrabenazine	1978
Tetrabenazine for involuntary movement disorders. The Medical journal of Australia, 1979, Jun-30, Volume: 1, Issue:13 Topics: Humans; Huntington Disease; Middle Aged; Movement Disorders; Tetrabenazine	1979
Neuroleptic malignant syndrome related to tetrabenazine introduction and haloperidol discontinuation in Huntington's disease. Clinical neuropharmacology, 1992, Volume: 15, Issue:1 Topics: Female; Haloperidol; Humans; Huntington Disease; Middle Aged; Neuroleptic Malignant Syndrome; Substance Withdrawal Syndrome; Tetrabenazine	1992
Depletion of monoamine transmitters by tetrabenazine in brain tissue in Huntington's disease. Neuropharmacology, 1988, Volume: 27, Issue:7 Topics: Brain Chemistry; Humans; Huntington Disease; Middle Aged; Neurotransmitter Agents; Tetrabenazine	1988
Iatrogenic parkinsonism in Huntington's chorea. Canadian journal of psychiatry. Revue canadienne de psychiatrie, 1986, Volume: 31, Issue:9 Topics: Chlorpromazine; Drug Interactions; Female; Humans; Huntington Disease; Middle Aged; Parkinson Disease, Secondary; Tetrabenazine	1986
Treatment of tardive dyskinesia: preliminary report on use of tetrabenazine. Canadian journal of psychiatry. Revue canadienne de psychiatrie, 1988, Volume: 33, Issue:1 Topics: Adult; Aged; Aged, 80 and over; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Female; Humans; Huntington Disease; Male; Middle Aged; Tetrabenazine	1988
Letter: Treatment of Huntington's chorea with tetrabenazine. Lancet (London, England), 1974, Mar-09, Volume: 1, Issue:7854 Topics: Deglutition Disorders; Humans; Huntington Disease; Pneumonia, Aspiration; Tetrabenazine	1974
Letter: Tetrabenazine in chorea. Lancet (London, England), 1974, Mar-23, Volume: 1, Issue:7856 Topics: Dose-Response Relationship, Drug; Follow-Up Studies; Humans; Huntington Disease; Tetrabenazine	1974
Editorial: Dopamine and G.A.B.A. in Huntington's chorea. Lancet (London, England), 1974, Nov-09, Volume: 2, Issue:7889 Topics: Aminobutyrates; Blood Platelets; Brain; Butyrophenones; Dopamine; gamma-Aminobutyric Acid; Humans; Huntington Disease; Phenothiazines; Reserpine; Tetrabenazine	1974
The effect of tetrabenazine in some hyperkinetic syndromes. Acta neurologica Scandinavica, 1968, Volume: 44, Issue:3 Topics: Adult; Age Factors; Aged; Facial Nerve; Humans; Huntington Disease; Hyperkinesis; Mastication; Middle Aged; Parkinson Disease, Secondary; Tetrabenazine	1968
Effect of tetrabenazine on extrapyramidal movement disorders. British medical journal, 1969, May-17, Volume: 2, Issue:5654 Topics: Chorea; Extrapyramidal Tracts; Female; Humans; Huntington Disease; Male; Movement Disorders; Parkinson Disease; Tetrabenazine	1969
Combined nitoman-pimozide treatment of Huntington's chorea and other hyperkinetic syndromes. Acta neurologica Scandinavica, 1970, Volume: 46, Issue:2 Topics: Humans; Huntington Disease; Movement Disorders; Tetrabenazine; Tranquilizing Agents	1970
Tetrabenazine for Huntington's chorea. British medical journal, 1970, Oct-03, Volume: 4, Issue:5726 Topics: Depression; Humans; Huntington Disease; Male; Middle Aged; Tetrabenazine	1970
Treatment of involuntary movement disorders with tetrabenazine. Journal of neurology, neurosurgery, and psychiatry, 1972, Volume: 35, Issue:2 Topics: Adolescent; Adult; Aged; Amantadine; Child; Depression; Dystonia Musculorum Deformans; Evaluation Studies as Topic; Female; Humans; Huntington Disease; Male; Middle Aged; Movement Disorders; Sleep Initiation and Maintenance Disorders; Tetrabenazine; Torticollis	1972
The suppression of involuntary movements with tetrabenazine. Scottish medical journal, 1972, Volume: 17, Issue:11 Topics: Adolescent; Adult; Aged; Ataxia; Athetosis; Depression; Diencephalon; Evaluation Studies as Topic; Female; Humans; Huntington Disease; Male; Middle Aged; Movement Disorders; Nausea; Parkinson Disease; Tetrabenazine; Time Factors; Tremor	1972
Drug treatment of diseases characterized by abnormal movements. Proceedings of the Royal Society of Medicine, 1973, Volume: 66, Issue:9 Topics: Chorea; Diazepam; Ethanol; Haloperidol; Humans; Huntington Disease; Levodopa; Movement Disorders; Myoclonus; Phenothiazines; Propranolol; Reserpine; Tetrabenazine; Tic Disorders; Torticollis; Tourette Syndrome; Tremor	1973